Compared with placebo, enteral lactoferrin supplementation did not decrease the incidence of NEC stage II or III, bronchopulmonary dysplasia, retinopathy of prematurity, invasive fungal infection, intraventricular hemorrhage, and urinary tract infection. The gene discussed is LTF; the disease is urinary tract infection.